Purpose One of the major obstacles of the clinical translation of 18 F-labeled arginine-glycine-aspartic acid (RGD) peptides has been the laborious multistep radiosynthesis. In order to facilitate the application of RGD-based positron emission tomography (PET) probes in the clinical setting we investigated in this study the feasibility of using the chelation reaction between Al 18 F and a macrocyclic chelatorconjugated dimeric RGD peptide as a simple one-step 18 F labeling strategy for development of a PET probe for tumor angiogenesis imaging. Methods Dimeric cyclic peptide E[c(RGDyK)] 2 (RGD 2 ) was first conjugated with a macrocyclic chelator, 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA), and the resulting bioconjugate NOTA-RGD 2 was then radiofluorinated via Al 18
F-labeled arginine-glycine-aspartic acid (RGD) peptides has been the laborious multistep radiosynthesis. In order to facilitate the application of RGD-based positron emission tomography (PET) probes in the clinical setting we investigated in this study the feasibility of using the chelation reaction between Al 18 F and a macrocyclic chelatorconjugated dimeric RGD peptide as a simple one-step 18 F labeling strategy for development of a PET probe for tumor angiogenesis imaging. Methods Dimeric cyclic peptide E[c(RGDyK)] 2 (RGD 2 ) was first conjugated with a macrocyclic chelator, 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA), and the resulting bioconjugate NOTA-RGD 2 was then radiofluorinated via Al 18 F intermediate to synthesize 18 F-AlF-NOTA-RGD 2 . Integrin binding affinities of the peptides were assessed by a U87MG cell-based receptor binding assay using 125 I-echistatin as the radioligand. The tumor targeting efficacy and in vivo profile of 18 F-AlF-NOTA-RGD 2 were further evaluated in a subcutaneous U87MG glioblastoma xenograft model by microPET and biodistribution. Results NOTA-RGD 2 was successfully 18 F-fluorinated with good yield within 40 min using the Al 18 F intermediate. The IC 50 of 19 F-AlF-NOTA-RGD 2 was determined to be 46± 4.4 nM. Quantitative microPET studies demonstrated that 18 F-AlF-NOTA-RGD 2 showed high tumor uptake, fast clearance from the body, and good tumor to normal organ ratios. Conclusion NOTA-RGD 2 bioconjugate has been successfully prepared and labeled with Al 18 F in one single step of radiosynthesis. The favorable in vivo performance and the short radiosynthetic route of 18 F-AlF-NOTA-RGD 2 warrant further optimization of the probe and the radiofluorination strategy to accelerate the clinical translation of
Introduction
Integrins are a family of transmembrane receptors, composed of 18 α and 8 β chains that can be combined to form 24 heterodimeric glycoproteins with distinct cellular and adhesive specificities. Among the integrin family, it has been well documented that integrin α v β 3 can elicit specific cell survival signals that facilitate vascular cell proliferation during angiogenesis but not in quiescent endothelium [1] . Integrin α v β 3 plays a vital role in the initiation, progression, and metastasis of many types of cancers [2] [3] [4] . Antagonists to integrins have been demonstrated to inhibit tumor angiogenesis, tumor growth, and metastasis in vivo [5] .
Therefore, visualization and quantification of tumor integrin α v β 3 expression levels are critically important not only for the diagnosis and staging of cancer but also for the selection of patients for anti-integrin treatments and monitoring of treatment efficacy. Positron emission tomography (PET) is a powerful modality for noninvasive imaging of different molecular targets and events thanks to its high sensitivity, reasonable spatial resolution, and good quantification ability. Developing PET probes to monitor integrin expression has been one of the most extensively studied areas in molecular imaging.
Arginine-glycine-aspartic acid (RGD) is a conserved amino acid motif that widely exists in many extracellular matrix proteins that bind to integrins. A variety of RGDbased probes have been developed for PET imaging of integrin α v β 3 [6, 7] . The positron emitter 18 F-fluoride has a physical half-life of 109.7 min which matches well with in vivo biological half-lives of many bioligands. 18 F also has almost 100% positron efficiency and is readily available from a medical cyclotron. Thus, it has been extensively used as a radiolabel for PET imaging [8] . However, most 18 F labeling procedures for peptides suffer from lengthy and tedious multistep radiosynthetic procedures. For example, 18 F-galacto-RGD that has been evaluated in human subjects requires four steps of radiosynthesis and three rounds of radio high performance liquid chromatography (radio-HPLC) purification [9] [10] [11] . The synthesis of another 18 F-labeled RGD peptide for clinical trials, 18 F-AH111585, involves two reaction pots and two radio-HPLC purifications [12] [13] [14] . A few other methods have been reported for radiofluorination of RGD peptides, including amide bond formation using N-succinimidyl 4- [17] . All of these 18 F radiolabeling strategies require multiple reaction steps. Moreover, it is very challenging to make these radiosynthetic processes fully automatic, which in turn sets a high technical barrier for using these PET probes in the clinical setting.
Very recently, a few pioneering studies on one-step 18 F labeling methods have been reported, based on fluorinesilicon chemistry [18, 19] , fluorine-boron chemistry [20] , and 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA)-AlF chelation chemistry [21] [22] [23] . However, so far none of these methods has been applied in developing RGD-based PET probes for tumor angiogenesis imaging. For radiofluorination strategies involving the NOTA-AlF chelation chemistry and fluorine-boron chemistry, the labeling procedure can be accomplished in water. From a biological perspective, these one-step and water-compatible reactions are ideal for incorporation of 18 F-fluoride into biologically active ligands, especially biomacromolecules that are only soluble in water.
In this study, we conjugated a dimeric cyclic RGD peptide, E [c(RGDyK)] 2 (abbreviated as RGD 2 ) with the NOTA chelator to prepare NOTA-RGD 2 (Fig. 1a, b) . This bioconjugate was then labeled with 18 F in one step via the simple 18 F-AlF chelation reaction in aqueous phase (Fig. 1c) )] at 0-5 min and was changed from 85% solvent A and 15% B at 5 min to 20% solvent A and 80% solvent B at 35 min. Analytical HPLC had the flow rate of 1 ml/min with a Vydac protein and peptide column (218TP510; 5 μm, 250×4.6 mm). The mobile phase gradient was changed from 95% solvent A and 5% B (0-2 min) to 35% solvent A and 65% solvent B at 32 min. The recorded data were processed using Chromeleon version 6.50 software. The UV absorbance was monitored at 218 nm and the identification of the peptides was confirmed based on the UV spectrum using a photodiode array (PDA) detector.
MicroPET scans were performed on a microPET R4 rodent model scanner (Siemens Medical Solutions USA, Inc., Knoxville, TN, USA). The scanner has a computercontrolled bed and 10.8-cm transaxial and 8-cm axial fields of view (FOVs). It has no septa and operates exclusively in the three-dimensional (3-D) list mode. Animals were placed near the center of the FOV of the scanner.
Preparation of NOTA-RGD 2
The chelator, NOTA, was purchased from CheMatch, France. It was activated by 1-ethyl-3-[3-(dimethylamino)propyl] carbodiimide (EDC) and N-hydroxysulfono-succinimide (SNHS) and conjugated with RGD 2 as reported earlier (Fig. 1b) [24] . The NOTA-RGD 2 conjugate was purified by a semi-preparative HPLC and characterized by analytical HPLC and matrix-assisted laser desorption/ionization time-offlight mass spectrometry (MALDI-TOF MS). The retention time (Rt) of the purified peptide was found to be 15.6 min, and the molecular mass was measured to be 1,637. 
Radiochemistry
The 18 F labeling reaction is shown in Fig. 1c . A QMA SepPak Light cartridge (Waters, Milford, MA, USA) fixed with 30 mCi (1.1 GBq) of 18 F-fluoride was washed with 2.5 ml of metal-free water. 18 F was then eluted from the cartridge with 400 μl of 0.4 M KHCO 3 , from which a 200-μl fraction was taken. The pH of the solution was adjusted to 4 with metal-free glacial acetic acid. AlCl 3 (2 mM, 3 μl) in 0.1 M sodium acetate buffer (pH 4) and 5 μl of NOTA-RGD 2 [60 mg/ml in dimethyl sulfoxide (DMSO)] were then added to the reaction solution sequentially. The reaction mixture was incubated at 100°C for 15 min. After dilution with 1 ml Fig. 1 of metal-free water, the crude mixture was purified with a semi-preparative HPLC. The fractions containing 18 F-AlF-NOTA-RGD 2 were collected and combined and the solvents were removed using a rotary evaporator. The product was reconstituted in phosphate-buffered saline (PBS, 1×, pH 7.4) and passed through a 0.22-μm Millipore filter into a sterile vial for in vitro and in vivo experiments. As a control experiment, RGD 2 was labeled with 18 F-NFP to make 18 F-FP-RGD 2 using the published method [25] .
Cell culture Human glioblastoma cell line U87MG was obtained from the American Type Culture Collection (Manassas, VA, USA) and were cultured in DMEM containing high glucose (GIBCO, Carlsbad, CA, USA), which was supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin. The cells were expanded in tissue culture dishes and kept in a humidified atmosphere of 5% CO 2 at 37°C. The medium was changed every other day. A confluent monolayer was detached with 0.05% trypsin-ethylenediaminetetraacetate (EDTA), 0.01 M PBS (pH 7.4), and dissociated into a single-cell suspension for further cell culture.
U87MG cell binding assay
This assay was performed as previously described [26] F-AlF-NOTA-RGD 2 ) in the integrin binding buffer [IBB, 25 mM Tris pH 7.4, 150 mM NaCl, 2 mM CaCl 2 , 1 mM MgCl 2 , 1 mM MnCl 2 , and 0.1% bovine serum albumin (BSA)] at room temperature for 1 h. The cell-bound radioactivity remaining after washing was determined by gamma counting. IC 50 values, which are the concentrations of the competing compound required to inhibit 50% of radioligand binding, were determined by nonlinear regression using GraphPad Prism (GraphPad Software, Inc., La Jolla, CA, USA). Experiments were performed with quadruplicate samples.
Mouse serum stability
The in vitro stability of 18 F-AlF-NOTA-RGD 2 was evaluated by incubation of 3.7 MBq (100 μCi) of the probe with mouse serum (1 ml) at 37°C. At different time points (0.5, 1, and 2 h), the solution was filtered using a NanoSep 3K centrifuge (Pall Corp., Port Washington, NY, USA) to isolate low molecular weight metabolites. The filtrates were analyzed by a reverse-phase HPLC under analytical conditions detailed above.
Animal biodistribution studies
Animal procedures were performed according to a protocol approved by the Stanford University Institutional Animal Care and Use Committee. Approximately 10×10 6 cultured U87MG cells were suspended in PBS and subcutaneously implanted in the right shoulders of female nude mice purchased from Charles River Laboratory (Wilmington, MA, USA). Tumors were allowed to grow to a size of 0.5-1 cm in diameter (2∼3 weeks). For biodistribution studies, the nude mice bearing U87MG xenografts (n=4 for each group) were injected with about 3.7 MBq (100 μCi) of 18 FAlF-NOTA-RGD 2 or 18 F-FP-RGD 2 through the tail vein and sacrificed at 2.0 h post-injection (p.i.). The blocking study of 18 F-AlF-NOTA-RGD 2 was performed by co-injection of the probe with c(RGDyK) (10 mg/kg body weight) through the tail vein. The tumor and normal organs of interest were removed and weighed, and their radioactivity was measured in a gamma counter. The radioactivity uptakes in the tumor and normal organs were expressed as a percentage of the injected radioactive dose per gram of tissue (%ID/g).
MicroPET imaging
For dynamic imaging studies, U87MG tumor-bearing mice were injected via the tail vein with approximately 3.7 MBq (100 μCi) of 18 F-AlF-NOTA-RGD 2 and microPET scans (6×20 s, 8×60 s, 10×150 s, total of 24 frames) were started approximately 2 min after probe injection and were continued for 35 min. For static scans, the mice bearing U87MG xenografts were injected with about 3.7 MBq (100 μCi) of 18 F-FP-RGD 2 or 18 F-AlF-NOTA-RGD 2 via the tail vein (n=4 for each group). Similarly, the blocking study was performed by injection of the probe with c (RGDyK) (10 mg/kg body weight) through the tail vein (n=4). At 0.5, 1, and 2 h p.i., the mice were anesthetized with isoflurane (5% for induction and 2% for maintenance in 100% O 2 ) using a knockdown box. With the help of a laser beam attached to the scanner, the mice were placed in the prone position near the center of the FOV of the scanner. The 3-min static scans were then obtained. Images were reconstructed by using a two-dimensional ordered subsets expectation maximization (OSEM) algorithm. No background correction was performed. Regions of interest (ROIs; 5 pixels for coronal and transaxial slices) were drawn over the tumor on decay-corrected whole-body coronal images. The maximum counts per pixel per minute were obtained from the ROI and converted to counts per milliliter per minute by using a calibration constant. With the assumption of a tissue density of 1 g/ml, the ROIs were converted to counts per gram per minute. Image ROI-derived %ID/g values were determined by dividing counts per gram per minute by injected dose. No attenuation correction was performed.
Statistical analysis
Quantitative data are expressed as mean ± SD. Means were compared using one-way analysis of variance (ANOVA) and Student's t test; p values of<0.05 were considered statistically significant.
Results

Chemistry and radiochemistry
The NOTA-RGD 2 was prepared by direct conjugation of RGD 2 with activated NOTA in 45% yield (Fig. 1b) . Both HPLC and mass spectroscopy were used to confirm the identity of the product. The 19 F-AlF-NOTA-RGD 2 was also synthesized for cell studies and used as a standard for characterization of its radioactive counterpart in HPLC. As shown in Fig. 2a , NOTA-RGD 2 and 19 F-AlF-NOTA-RGD 2 could be clearly separated by analytical HPLC. For purification of the radioactive product, a difference of 0.6 min on retention time on a semi-preparative HPLC was observed between 18 F-AlF-NOTA-RGD 2 and the unlabeled peptide (Fig. 2b) . The whole radiosynthesis was accomplished within 40 min with a decay-corrected yield of 17.9% and radiochemical purity of more than 95%. The specific activity of purified 18 F-AlF-NOTA-RGD 2 was calculated as 300-400 mCi/μmol. 18 F-FP-RGD 2 (Fig. 1d) was synthesized using the published method in 15.4% decay-corrected yield starting with 18 F-fluoride [25] .
Cell binding assay
The competitive cell binding assay was used to determine the receptor binding affinity of 19 F-AlF-NOTA-RGD 2 and RGD 2 (Fig. 3) 18 F-AlF-NOTA-RGD 2 displayed good stability in mouse serum (Fig. 4) . After incubation in serum, more than 95% activity (decay corrected) was recovered for HPLC analysis. The percentage of intact probes remained more than 95% after 0.5, 1, and 2 h incubation in mouse serum at 37°C. Defluorination was not observed for the probe incubated with mouse serum up to 2 h. Overall, 18 F-AlF-NOTA-RGD 2 could be reliably produced and demonstrated good in vitro stability.
MicroPET imaging studies
The in vivo pharmacokinetic profile and tumor targeting property of 18 F-AlF-NOTA-RGD in U87MG tumor-bearing nude mice were evaluated by 35-min dynamic microPET scans followed by static scans at 1 and 2 h p.i. As shown in Fig. 5a , the probe was rapidly cleared from the renal system as determined by ROI analysis of the kidneys. At the first 3 min after tail vein injection, radioactivity rapidly accumulated in kidneys (31.1±4.3%ID/g) but decreased to 10.5±0.5%ID/g at 10 min p.i. In contrast, tumor uptake peaked (5.3±1.2%ID/g) at a very early time point (3 min p.i.) and was maintained throughout the whole dynamic scan frames. Low levels of liver and muscle uptakes were also observed (Fig. 5a) .
Representative decay-corrected coronal images of static scans at different time points after injection are shown in Fig. 5b . The U87MG tumors were clearly visualized with good tumor to background contrast for both 18 F-AlF-NOTA-RGD 2 and 18 F-FP-RGD 2 . For 18 F-AlF-NOTA-RGD 2 , the tumor uptake was 5.7±2.1, 5.3±1.7, and 1.9±0.7%ID/g at 0.5, 1, and 2 h p.i., respectively (Fig. 5c ). For 18 F-FP-RGD 2 , the tumor uptake was 4.0±1.1, 2.8±0.7, and 1.1±0.2%ID/g at 0.5, 1, and 2 h p.i., respectively (Fig. 5e) . At 1 h p.i., the tumor uptake of 18 F-AlF-NOTA-RGD 2 is significantly higher than that of 18 F-FP-RGD 2 (p<0.05). Both of the radiolabeled probes were excreted mainly through the kidneys. Liver, kidney, and muscle uptakes of 18 F-AlF-NOTA-RGD 2 and 18 F-FP-RGD 2 had no significant difference (p>0.05) at 2 h p.i. in the static scans.
The microPET images at 0.5, 1, and 2 h p.i. of U87MG tumor-bearing mice injected with 18 F-AlF-NOTA-RGD 2 and a blocking dose of c(RGDyK) are shown in Fig. 5b . The U87MG tumor uptake was reduced to the background level and the uptake values were 0.46±0.05, 0.29±0.05, and 0.14± 0.09%ID/g at 0.5, 1, and 2 h p.i., respectively, confirming the integrin α v β 3 -specific targeting of 18 F-AlF-NOTA-RGD 2 in the integrin-positive U87MG tumor. The uptakes in most of the normal organs (e.g., liver, kidneys, and muscle) were also lower than those without co-injection of c(RGDyK) (Fig. 5d) . These results are consistent with previous literature, which is contributed by the expression of integrin receptors in many normal tissues [30, 31] . Moreover, the reduced uptake of the probe in normal organs might also be caused by the potential toxicity effect of a large dose of c(RGDyK).
The tumor to normal organ ratios of 18 F-AlF-NOTA-RGD 2 and 18 F-FP-RGD 2 were also calculated for comparison of their in vivo properties at 2 h p.i. (Fig. 5f ). Although 18 FAlF-NOTA-RGD 2 had higher tumor uptakes than those of 18 F-FP-RGD 2 , the tumor to normal organ ratios showed no significant difference for these two probes (p>0.05).
Biodistribution studies
To validate microPET quantifications, we also performed a biodistribution experiment by directly sampling tumors and normal organs of U87MG tumor-bearing mice 2 h after tail vein injection of F-FP-RGD 2 were 2.3±0.9 and 1.3±0.8%ID/g, respectively. Except for liver and kidneys, the uptake values in the other major organs for both 18 F-AlF-NOTA-RGD 2 and 18 F-FP-RGD 2 were less than 1%ID/g. Of note, the bone uptake of 18 F-AlF-NOTA-RGD 2 was only 0.53±0.14%ID/g, which is consistent with its high stability in mouse serum. For the blocking study, a decrease of radioactivity was observed in all dissected tissues and organs (black bars in Fig. 6 ) with the change of tumor uptake being the most significant, as it was reduced markedly from 2.26±0.91 to 0.18±0.02%ID/g at 2 h p.i. Fig. 4 18 F-AlF-NOTA-RGD 2 stability in mouse serum after incubation at 37°C for 0.5, 1, and 2 h E. 
Discussion
The armamentarium of 18 F and other radionuclide-labeled RGD peptides for PET imaging of tumor angiogenesis has expanded exponentially in the last decade. Two prominent amino-specific prosthetic agents, 18 F-NFP and 18 F-SFB, have been widely used for labeling RGD peptides and a variety of applications have been achieved by these two labeling methods. However, to obtain the final radiofluorinated product multiple radiosynthetic steps are almost always required. As a result, the complex radiosynthesis has become a major challenge for automation and subsequently a significant barrier for large-scale and high-radioactivity production for clinical translation. Even the most current 18 F-labeled RGD peptides being evaluated in clinics suffer from the laborious radiolabeling procedures [27] . Therefore, the recently reported novel 18 F labeling methods [20] [21] [22] [23] 28] inspired us to pursue a straightforward, single-step, and powerful labeling strategy to radiofluorinate RGD peptides for future preclinical and clinical applications. In this study, we explored the 18 F-AlF-NOTA labeling method pioneered by McBride et al. [23] and evaluated our product 18 F-AlF-NOTA-RGD 2 in U87MG tumor-bearing mice.
Using the published optimal reaction condition [21] , we radiofluorinated NOTA-RGD 2 with 17.9% decay-corrected yield within 40 min after bombardment. Figure 2b shows the semi-preparative HPLC result for the purification of the final product. The 18 F-labeled NOTA-RGD 2 is eluted at 12.5 min, while the unlabeled NOTA-RGD 2 is washed out at 13.1 min. The good separation of the unlabeled precursor from the PET probe results in the high specific activity of 18 F-AlF-NOTA-RGD 2 . Of note, in the published literature two rapid interchangeable isomers that accounted for the 18 F-labeled products were obtained [21] [22] [23] . However, in our study only one radiolabeled product was observed, presumably because a different peptide was used for radiosynthesis.
Among all the 18 F-labeled RGD peptides reported so far, at least one round of azeotropic drying is needed in the whole synthesis scheme. This step requires high-quality drying instruments and good techniques from radiochemists. Failure to dry 18 F-fluoride properly could result in low yields or even no product. With the 18 F-AlF-NOTA labeling method, however, water is used as the solvent for reaction and thus the drying step is no longer necessary, which is a significant advantage over conventional methods and makes this method of 18 F labeling of RGD peptides even more robust and attractive. The F-AlF-NOTA-RGD 2 was first evaluated by dynamic microPET in the U87MG glioblastoma xenograft mouse model, which has been well established to have a high integrin α v β 3 expression [29] . The probe showed prominent uptake in the tumor and a predominant renal clearance. On a side-by-side comparison with 18 F-labeled dimeric RGD using conventional 18 F-NFP synthon, higher tumor uptakes could be observed for 18 F-AlF-NOTA-RGD 2 at 0.5 and 1 h p.i. than those of 18 F-FP-RGD 2 at the same time points (p<0.05). However, similar tumor to normal organ ratios were obtained for the two probes despite the statistically significant difference in uptake values of the tumor (Fig. 5f) . The results of the biodistribution study demonstrate that both good-yield, and easy-operation protocol for production of 18 FAlF-NOTA-RGD 2 warrants further applications in labeling a variety of other biomolecules. For now, it can serve as a very promising labeling approach for preparation of RGD-based PET probes and can facilitate the translation of these probes into clinical applications.
Conclusion
NOTA-RGD 2 conjugate was successfully prepared and radiolabeled with 18 F-fluoride via Al 18 F intermediate with good yield. This fluorination method for the RGD peptide was very simple and straightforward and the labeled product 18 F-AlF-NOTA-RGD 2 exhibits excellent in vitro serum stability and in vivo tumor imaging properties. The favorable in vivo performance and the easy production method of 18 F-AlF-NOTA-RGD 2 warrant further optimization of this probe as well as the radiofluorination strategy so that the clinical translation of 18 F-labeled RGD peptides can be accelerated.
